These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 504931)

  • 1. Behaviour of platelet adhesiveness and of dilute clot blood lysis time in hyperlipoproteinemic subjects.
    Zdrenghea D; Stef C; Cucuianu M; Vlaicu R
    Med Interne; 1979; 17(3):273-7. PubMed ID: 504931
    [No Abstract]   [Full Text] [Related]  

  • 2. Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
    Cucuianu M; Knauer O; Roman S
    Thromb Haemost; 1991 Nov; 66(5):586-91. PubMed ID: 1725069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibrinolytic capacity after exertion in atherogenic hyperlipoproteinemias].
    Zdrenghea D; Mărcuşu C; Cucuianu M; Rentsch S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(5):435-40. PubMed ID: 44567
    [No Abstract]   [Full Text] [Related]  

  • 4. Behaviour of uricemia in hyperlipoproteinemic subjects.
    Zdrenghea D; Marta D; Constantinescu M; Cucuianu M
    Med Interne; 1980; 18(4):385-90. PubMed ID: 7455583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. IV. Blood coagulation and fibrinolysis indicators].
    Borodin M; Jurek D; Gregorczyk J; Pieczul-Mróz J; Cwajda H
    Przegl Lek; 1983; 40(10):727-32. PubMed ID: 6665208
    [No Abstract]   [Full Text] [Related]  

  • 6. [HDL, HDL2 and HDL3 cholesterol in various types of hyperlipoproteinemia in relation to clinical signs of arteriosclerosis].
    Sznajderman M; Zawadzki Z
    Kardiol Pol; 1986; 29(3):194-203. PubMed ID: 3773408
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro effect of p-chlormercuribenzoate upon dilute blood clot lysis time in hyperlipemia.
    Cucuianu MP; Stef C; Zdrenghea D; Popescu O
    Thromb Haemost; 1979 Oct; 42(3):929-44. PubMed ID: 505407
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias].
    Reiner Z; Salzer B; Kes P
    Acta Med Iugosl; 1988; 42(5):353-62. PubMed ID: 3245481
    [No Abstract]   [Full Text] [Related]  

  • 9. In vivo platelet activity and lipoprotein patterns in coronary artery disease.
    Goubran F; Maklady F; Saad M; el-Ashry M
    Wien Klin Wochenschr; 1986 Apr; 98(7):209-11. PubMed ID: 3705598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Beta 2 glycoprotein I analysis in patients with hyperlipoproteinemia, arteriosclerotic occlusive disease and diabetes mellitus].
    Müller G; Biering A; Lux E; Richter V
    Z Gesamte Inn Med; 1983 May; 38(10):282-4. PubMed ID: 6613192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood coagulation and fibrinolysis systems in primary hyperlipoproteinemias].
    Berent H; Uchman B
    Pol Arch Med Wewn; 1983 Sep; 70(3):131-4. PubMed ID: 6657492
    [No Abstract]   [Full Text] [Related]  

  • 12. [Study of phospholipids in primary hyperlipoproteinemias].
    Kuczyńska K
    Pol Arch Med Wewn; 1979 Jul; 62(1):29-40. PubMed ID: 503884
    [No Abstract]   [Full Text] [Related]  

  • 13. [Functional status of thrombocytes and the anti-aggregative activity of the vascular wall in dyslipoproteinemias and ischemic heart disease].
    Mikhailova IA; Lipovetskiĭ BM; Magracheva EIa; Gurevich VS
    Ter Arkh; 1989; 61(2):101-4. PubMed ID: 2727909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V; Klör HU; Wechsler JG; Ditschuneit H
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Platelet aggregation in whole blood and thromboxane B2 in type II and IV hyperlipidemia].
    Craveri A; Lanfredini M; Citella C; Barbesti S; Braconaro F; Marzocchi B; Colombo L
    Minerva Med; 1987 Dec; 78(23):1739-43. PubMed ID: 3696450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of n-3 fatty acids on lipids and haemostasis in patients with type IIa and type IV hyperlipidaemia.
    Schmidt EB; Ernst E; Varming K; Pedersen JO; Dyerberg J
    Thromb Haemost; 1989 Sep; 62(2):797-801. PubMed ID: 2814927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelet aggregation in hyperlipoproteinemias].
    Calabrese S; Da Col PG; Giansante C; Morgante O; Cattin L
    Minerva Med; 1982 May; 73(22):1541-6. PubMed ID: 7088380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Increase in the fibrinolytic activity in patients with hyperlipoproteinemias type IV treated with bezafibrate].
    Obispo TM; García Fradé LJ; García Avelló A; César J; Sastre A; Navarro JL
    Rev Clin Esp; 1988 Feb; 182(3):151-4. PubMed ID: 3368592
    [No Abstract]   [Full Text] [Related]  

  • 19. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antithrombogenic activity of the vascular wall, hemostasis, and rheological characteristics of blood in patients with unstable angina pectoris and various types of hyperlipoproteinemia].
    Kirichuk VF; Voskoboĭ IV
    Ter Arkh; 2000; 72(12):47-50. PubMed ID: 11201832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.